132 related articles for article (PubMed ID: 37801615)
1. Progressively Enhancing Stemness of Adoptively Transferred T Cells with PI3Kδ Blockade Improves Metabolism and Antitumor Immunity.
Rangel Rivera GO; Dwyer CJ; Knochelmann HM; Smith AS; Aksoy BA; Cole AC; Wyatt MM; Kumaresan S; Thaxton JE; Lesinski GB; Paulos CM
Cancer Res; 2024 Jan; 84(1):69-83. PubMed ID: 37801615
[TBL] [Abstract][Full Text] [Related]
2. The degree of T cell stemness differentially impacts the potency of adoptive cancer immunotherapy in a Lef-1 and Tcf-1 dependent manner.
Rangel Rivera GO; Dwyer CJ; Knochelmann HM; Smith AS; Aksoy A; Cole AC; Wyatt MM; Thaxton JE; Lesinski GB; Paulos CM
bioRxiv; 2023 Mar; ():. PubMed ID: 36945574
[TBL] [Abstract][Full Text] [Related]
3. New insights into the stemness of adoptively transferred T cells by γc family cytokines.
Luo M; Gong W; Zhang Y; Li H; Ma D; Wu K; Gao Q; Fang Y
Cell Commun Signal; 2023 Dec; 21(1):347. PubMed ID: 38049832
[TBL] [Abstract][Full Text] [Related]
4.
Hu X; Majchrzak K; Liu X; Wyatt MM; Spooner CJ; Moisan J; Zou W; Carter LL; Paulos CM
Cancer Res; 2018 Jul; 78(14):3888-3898. PubMed ID: 29769201
[TBL] [Abstract][Full Text] [Related]
5. Ex vivo blockade of PI3K gamma or delta signaling enhances the antitumor potency of adoptively transferred CD8
Dwyer CJ; Arhontoulis DC; Rangel Rivera GO; Knochelmann HM; Smith AS; Wyatt MM; Rubinstein MP; Atkinson C; Thaxton JE; Neskey DM; Paulos CM
Eur J Immunol; 2020 Sep; 50(9):1386-1399. PubMed ID: 32383488
[TBL] [Abstract][Full Text] [Related]
6. BLIMP1 and NR4A3 transcription factors reciprocally regulate antitumor CAR T cell stemness and exhaustion.
Jung IY; Narayan V; McDonald S; Rech AJ; Bartoszek R; Hong G; Davis MM; Xu J; Boesteanu AC; Barber-Rotenberg JS; Plesa G; Lacey SF; Jadlowsky JK; Siegel DL; Hammill DM; Cho-Park PF; Berger SL; Haas NB; Fraietta JA
Sci Transl Med; 2022 Nov; 14(670):eabn7336. PubMed ID: 36350986
[TBL] [Abstract][Full Text] [Related]
7. Enhanced antitumor immunity through sequential targeting of PI3Kδ and LAG3.
Lauder SN; Smart K; Kersemans V; Allen D; Scott J; Pires A; Milutinovic S; Somerville M; Smart S; Kinchesh P; Lopez-Guadamillas E; Hughes E; Jones E; Scurr M; Godkin A; Friedman LS; Vanhaesebroeck B; Gallimore A
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33093155
[TBL] [Abstract][Full Text] [Related]
8. Neoantigen-specific stem cell memory-like CD4
Brightman SE; Becker A; Thota RR; Naradikian MS; Chihab L; Zavala KS; Ramamoorthy Premlal AL; Griswold RQ; Dolina JS; Cohen EEW; Miller AM; Peters B; Schoenberger SP
Nat Immunol; 2023 Aug; 24(8):1345-1357. PubMed ID: 37400675
[TBL] [Abstract][Full Text] [Related]
9. B cells imprint adoptively transferred CD8
Smith AS; Knochelmann HM; Wyatt MM; Rangel Rivera GO; Rivera-Reyes AM; Dwyer CJ; Ware MB; Cole AC; Neskey DM; Rubinstein MP; Liu B; Thaxton JE; Bartee E; Paulos CM
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35017148
[TBL] [Abstract][Full Text] [Related]
10. Metabolic reprogramming via an engineered PGC-1α improves human chimeric antigen receptor T-cell therapy against solid tumors.
Lontos K; Wang Y; Joshi SK; Frisch AT; Watson MJ; Kumar A; Menk AV; Wang Y; Cumberland R; Lohmueller J; Carrizosa E; Boyerinas B; Delgoffe GM
J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 36914208
[TBL] [Abstract][Full Text] [Related]
11. Targeting Protein Tyrosine Phosphatase 22 Does Not Enhance the Efficacy of Chimeric Antigen Receptor T Cells in Solid Tumors.
Du X; Darcy PK; Wiede F; Tiganis T
Mol Cell Biol; 2022 Mar; 42(3):e0044921. PubMed ID: 35041491
[TBL] [Abstract][Full Text] [Related]
12. Multifactorial T-cell hypofunction that is reversible can limit the efficacy of chimeric antigen receptor-transduced human T cells in solid tumors.
Moon EK; Wang LC; Dolfi DV; Wilson CB; Ranganathan R; Sun J; Kapoor V; Scholler J; Puré E; Milone MC; June CH; Riley JL; Wherry EJ; Albelda SM
Clin Cancer Res; 2014 Aug; 20(16):4262-73. PubMed ID: 24919573
[TBL] [Abstract][Full Text] [Related]
13. NOTCH1 signaling during CD4+ T-cell activation alters transcription factor networks and enhances antigen responsiveness.
Wilkens AB; Fulton EC; Pont MJ; Cole GO; Leung I; Stull SM; Hart MR; Bernstein ID; Furlan SN; Riddell SR
Blood; 2022 Nov; 140(21):2261-2275. PubMed ID: 35605191
[TBL] [Abstract][Full Text] [Related]
14. Next-Generation Manufacturing Protocols Enriching T
Arcangeli S; Falcone L; Camisa B; De Girardi F; Biondi M; Giglio F; Ciceri F; Bonini C; Bondanza A; Casucci M
Front Immunol; 2020; 11():1217. PubMed ID: 32636841
[TBL] [Abstract][Full Text] [Related]
15. LRP11 promotes stem-like T cells via MAPK13-mediated TCF1 phosphorylation, enhancing anti-PD1 immunotherapy.
Sun L; Ma Z; Zhao X; Tan X; Tu Y; Wang J; Chen L; Chen Z; Chen G; Lan P
J Immunother Cancer; 2024 Jan; 12(1):. PubMed ID: 38272565
[TBL] [Abstract][Full Text] [Related]
16. Enhanced Cancer Immunotherapy by Chimeric Antigen Receptor-Modified T Cells Engineered to Secrete Checkpoint Inhibitors.
Li S; Siriwon N; Zhang X; Yang S; Jin T; He F; Kim YJ; Mac J; Lu Z; Wang S; Han X; Wang P
Clin Cancer Res; 2017 Nov; 23(22):6982-6992. PubMed ID: 28912137
[No Abstract] [Full Text] [Related]
17. Solid Tumor Microenvironment Can Harbor and Support Functional Properties of Memory T Cells.
Sullivan PM; Reed SJ; Kalia V; Sarkar S
Front Immunol; 2021; 12():706150. PubMed ID: 34867942
[TBL] [Abstract][Full Text] [Related]
18. PTP1B Is an Intracellular Checkpoint that Limits T-cell and CAR T-cell Antitumor Immunity.
Wiede F; Lu KH; Du X; Zeissig MN; Xu R; Goh PK; Xirouchaki CE; Hogarth SJ; Greatorex S; Sek K; Daly RJ; Beavis PA; Darcy PK; Tonks NK; Tiganis T
Cancer Discov; 2022 Mar; 12(3):752-773. PubMed ID: 34794959
[TBL] [Abstract][Full Text] [Related]
19. MEK inhibition reprograms CD8
Verma V; Jafarzadeh N; Boi S; Kundu S; Jiang Z; Fan Y; Lopez J; Nandre R; Zeng P; Alolaqi F; Ahmad S; Gaur P; Barry ST; Valge-Archer VE; Smith PD; Banchereau J; Mkrtichyan M; Youngblood B; Rodriguez PC; Gupta S; Khleif SN
Nat Immunol; 2021 Jan; 22(1):53-66. PubMed ID: 33230330
[TBL] [Abstract][Full Text] [Related]
20. Lactate dehydrogenase inhibition synergizes with IL-21 to promote CD8
Hermans D; Gautam S; García-Cañaveras JC; Gromer D; Mitra S; Spolski R; Li P; Christensen S; Nguyen R; Lin JX; Oh J; Du N; Veenbergen S; Fioravanti J; Ebina-Shibuya R; Bleck C; Neckers LM; Rabinowitz JD; Gattinoni L; Leonard WJ
Proc Natl Acad Sci U S A; 2020 Mar; 117(11):6047-6055. PubMed ID: 32123114
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
